Retatrutide 20mg Price and Research: Trial Evidence Review

Retatrutide (research code LY3437943) is an investigational single-peptide triple receptor agonist developed by Eli Lilly that engages the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the GLP-1 receptor (GLP-1R) in a single molecule. Three peer-reviewed phase 2 publications now cover the compound in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD) study populations. This article reviews the receptor-level mechanism, walks through what the published trials actually measured and reported, outlines formulation and handling context for laboratory researchers, and explains how AminoLabz documents retatrutide lots with batch-specific certificates of analysis. Throughout, retatrutide is discussed strictly as a research compound for in vitro laboratory use.

What Retatrutide Is: A Triple-Receptor Mechanism

Retatrutide’s defining feature is simultaneous activity at all three receptors. The discovery report, Coskun et al., Cell Metabolism, 2022, describes LY3437943 as a novel triple agonist peptide at the glucagon receptor, the GIP receptor, and the GLP-1 receptor. In vitro receptor assays characterized the compound as having balanced GCGR and GLP-1R activity with greater activity at GIPR. The published abstract states this qualitatively and does not report numeric potency values, so this article does not cite specific EC50 or activity percentages for any receptor.

Preclinical work in the same report used obese mouse models alongside cell-based assays. Administration of the peptide decreased body weight and improved glycemic control in those models, and the authors attribute the weight effect to the combination of GCGR-mediated increases in energy expenditure with GIPR- and GLP-1R-driven reductions in calorie intake. That mechanistic decomposition is what distinguishes a triple agonist from the single- and dual-agonist incretin peptides studied previously.

As the AminoLabz product copy notes, preclinical research continues to examine the mechanistic basis of triple receptor activity, receptor selectivity profiles, and downstream signaling pathways. Quantitative receptor pharmacology beyond the qualitative description above has not been verified for this review and is deliberately omitted.

From Discovery Research to Clinical Proof of Concept

The same Cell Metabolism report carried LY3437943 from discovery chemistry into first-in-human testing. In a phase 1 single-ascending-dose study, the paper reports safety and tolerability described as similar to other incretin-based agents, a pharmacokinetic profile that supported once-weekly administration within the trial structure, and body-weight reduction persisting up to day 43 after a single dose in that phase 1 population.

These were phase 1 observations in a small human trial population. Their role in the research record is to justify the larger randomized studies summarized below, not to predict outcomes in any other context.

Published Phase 2 Evidence: Obesity, Type 2 Diabetes, and MASLD

Dose-arm labels below, such as 1, 4, 8, or 12 mg, and the once-weekly trial administration structure are identifiers of the published trial designs, reproduced solely to report what was studied. They are not administration guidance of any kind, and this article contains no dosing, injection, or protocol instructions.

Obesity: Jastreboff et al., New England Journal of Medicine, 2023

The phase 2 obesity trial (ClinicalTrials.gov NCT04881760) randomized 338 adults with a BMI of 30 or higher, or 27 to below 30 with at least one weight-related comorbidity, to once-weekly retatrutide arms labeled 1, 4, 8, or 12 mg or to placebo for 48 weeks. The primary endpoint was percentage change in body weight from baseline to 24 weeks.

Least-squares-mean body-weight change at 24 weeks was -7.2% in the 1 mg arm, -12.9% in the pooled 4 mg arms, -17.3% in the pooled 8 mg arms, and -17.5% in the 12 mg arm, versus -1.6% with placebo. At 48 weeks, the corresponding values were -8.7%, -17.1%, -22.8%, and -24.2% versus -2.1%. The share of participants with a 15% or greater body-weight reduction at 48 weeks was 60% in the pooled 4 mg arms, 75% in the pooled 8 mg arms, and 83% in the 12 mg arm, versus 2% with placebo. Gastrointestinal adverse events were the most commonly reported, were dose-related, and were mostly mild to moderate, partially mitigated by the trial’s lower starting-dose design; dose-dependent heart-rate increases peaked at 24 weeks and declined thereafter.

These figures are observations within that trial population, not outcome guarantees in any other setting.

Type 2 Diabetes: Rosenstock et al., The Lancet, 2023

The phase 2 type 2 diabetes trial (NCT04867785) was conducted at 42 US centers and randomized 281 participants with HbA1c of 7.0 to 10.5% and BMI of 25 to 50 to retatrutide arms, placebo, or an active comparator, dulaglutide 1.5 mg; 237 participants (84%) completed the trial. The primary endpoint was change in HbA1c from baseline to 24 weeks.

Least-squares-mean HbA1c change at 24 weeks ranged from -0.43% in the 0.5 mg arm to -2.02% in the 12 mg escalation arm, versus -0.01% with placebo and -1.41% with dulaglutide 1.5 mg. Body weight declined dose-dependently at 36 weeks, up to -16.94% in the 12 mg arm versus -3.00% with placebo and -2.02% with dulaglutide. Gastrointestinal adverse events were mild to moderate; the trial reported no severe hypoglycemia and no deaths. The authors state that these phase 2 data informed dose selection for a subsequent phase 3 programme.

MASLD: Sanyal et al., Nature Medicine, 2024

A phase 2a substudy of the 48-week obesity trial, conducted under the same registry identifier NCT04881760, randomized 98 participants with MASLD and at least 10% liver fat to once-weekly retatrutide arms labeled 1, 4, 8, or 12 mg or placebo for 48 weeks. The primary objective was mean relative change in liver fat at 24 weeks.

Liver fat decreased by a mean relative -42.9% in the 1 mg arm, -57.0% in the 4 mg arm, -81.4% in the 8 mg arm, and -82.4% in the 12 mg arm, versus +0.3% with placebo, with all comparisons reported at P<0.001. The proportion of participants reaching liver fat below 5% at 24 weeks was 27%, 52%, 79%, and 86% across the four arms, respectively, versus 0% with placebo.

Formulation and Handling Context for Laboratory Researchers

The AminoLabz catalog lists retatrutide in four mass-based research sizes: 10MG, 20MG, 40MG, and 60MG, per the site’s public product feed. As of the September 2026 feed snapshot, the 10MG, 20MG, and 40MG sizes are in stock and the 60MG size is out of stock. The catalog also carries separate laboratory supplies, including empty vials and bacteriostatic water, listed under the feed’s supplies category.

For any retatrutide lot, the practical research questions are documentation questions: what batch was produced, what third-party testing covers it, and can a researcher match the certificate of analysis to the exact lot received. Storage and handling of research peptides follow the supplier’s product documentation and standard institutional laboratory practice; this article intentionally provides no preparation or administration instructions of any kind.

Why Researchers Source Retatrutide from AminoLabz

Researchers comparing retatrutide 20mg price across suppliers generally care less about the sticker number than about what documentation stands behind each batch. The canonical Retatrutide 20mg product page lists a current price of $140 with a regular price of $175 and in-stock status, per the public feed. The full retatrutide line in the September 2026 feed snapshot reads: RETATRUTIDE 10MG at $88 (in stock), RETATRUTIDE 20MG at $140 (regular price $175, in stock), RETATRUTIDE 40MG at $248 (in stock), and RETATRUTIDE 60MG at $336 (out of stock).

The more consequential difference is documentation. AminoLabz publishes third-party lab test results for every batch it carries on its COA index, with batch-specific certificates for retatrutide lots, including the 10, 20, and 40 mg sizes, listed there. A laboratory can therefore match a received lot to a named batch document before any in vitro work begins. Catalog copy is written in the same clinical register as the published literature, names the research code LY3437943 explicitly, and frames every product as strictly for in vitro laboratory research.

Frequently Asked Questions

Is retatrutide the same compound as LY3437943?

Yes. LY3437943 is the research code used in the discovery paper and the clinical trial literature for retatrutide, the Eli Lilly triple receptor agonist. Both the product copy and the published papers use the code, so researchers can cross-reference catalog listings directly against the cited studies.

What does “triple receptor agonist” mean at the receptor level?

It means a single peptide engages three receptors simultaneously: GCGR, GIPR, and GLP-1R. The published in vitro characterization (Coskun et al., Cell Metabolism, 2022) describes balanced GCGR and GLP-1R activity with greater GIPR activity. Numeric potency values are not stated in that abstract and are not repeated here.

How far has clinical research on retatrutide progressed?

Phase 2 results are published for obesity (Jastreboff et al., New England Journal of Medicine, 2023), type 2 diabetes (Rosenstock et al., The Lancet, 2023), and a MASLD substudy (Sanyal et al., Nature Medicine, 2024). The Lancet paper’s interpretation notes that the phase 2 data informed dose selection for a subsequent phase 3 programme. Phase 3 results are not cited in this article because they were not verified for this review.

What does retatrutide cost at AminoLabz?

Per the September 2026 public product feed: RETATRUTIDE 10MG at $88, RETATRUTIDE 20MG at $140 with a regular price of $175, RETATRUTIDE 40MG at $248, and RETATRUTIDE 60MG at $336. Stock status at that snapshot was in stock for the first three sizes and out of stock for 60MG. Prices and stock can change, so the product feed and the product page are the current sources of truth.

How can a laboratory verify a specific retatrutide batch?

The COA index linked in the sourcing section above lists batch-specific, third-party certificates of analysis, including retatrutide 10, 20, and 40 mg lots. Matching the lot identifier on the certificate to the batch received is the core documentation step for an in vitro research workflow. This is document verification for laboratory research purposes, not preparation guidance.

This article is for educational and research purposes only. AminoLabz products are intended strictly for in vitro laboratory research. Not for human or veterinary use. Not approved by the FDA.